International Journal of
Reproductive Biomedicine
Thu, Apr 25, 2024
[Archive]
Volume 17, Issue 7 (July 2019 2019)
IJRM 2019, 17(7): 487-492 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ibanoglu M C, Sanhal C Y, Ozgu-Erdinc S, Kara O, Yucel A, Uygur D. Maternal plasma fetuin-A levels in fetal growth
restriction: A case-control study. IJRM 2019; 17 (7) :487-492
URL: http://ijrm.ir/article-1-1581-en.html
URL: http://ijrm.ir/article-1-1581-en.html
Mujde Can Ibanoglu1 
, Cem Yasar Sanhal1 , Seval Ozgu-Erdinc * 2, Ozgur Kara1 , Aykan Yucel2 , Dilek Uygur2
, Cem Yasar Sanhal1 , Seval Ozgu-Erdinc * 2, Ozgur Kara1 , Aykan Yucel2 , Dilek Uygur2
1- University of Health Sciences, Dr. Zekai Tahir Burak Women’s Health Care, Education and Research Hospital, Ankara, Turkey.
2- University of Health Sciences, Dr. Zekai Tahir Burak Women’s Health Care, Education and Research Hospital, Ankara, Turkey
2- University of Health Sciences, Dr. Zekai Tahir Burak Women’s Health Care, Education and Research Hospital, Ankara, Turkey
Abstract: (2697 Views)
Background: Higher Fetuin-A (FA) concentrations were found to be associated with obesity and there is an interest to the relation between maternal FA and pregnancy outcomes.
Objective: In this study, our aim was to evaluate the association of maternal plasma levels of FA with fetal growth restriction (FGR).
Materials and Methods: 41 pregnant women with FGR and 40 controls were recruited in this case-control study between July and November 2015. At the diagnosis of FGR, venous blood samples (10 cc) were obtained for FA analysis.
Results: Maternal plasma FA levels were significantly higher in fetal growth-restricted pregnant women compared with controls (19.3 ± 3.0 ng/ml vs 25.9 ± 6.8 ng/ml, p = 0.001). Area under receiver operating characteristic curve analysis of FA in FGR was 0.815 (95% confidence interval (CI): 0.718-0.912, p < 0.001). The maternal FA levels with values more than 22.5 ng/ml had a sensitivity of about 73.17% (95% CI: 56.79- 85.25) and a specificity of about 82.5% (95% CI: 66.64-92.11) with positive and negative predictive values of about 81.08% (95% CI: 64.29-91.45) and 75% (95% CI: 59.35-86.30), respectively. Therefore, the diagnostic accuracy was obtained about 77.78%.
Conclusion: The results of this study show higher maternal plasma levels of FA in FGR. Further studies are needed in order to demonstrate the long-term effects of FA in pregnancies complicated with FGR and early prediction of FFGR.
Objective: In this study, our aim was to evaluate the association of maternal plasma levels of FA with fetal growth restriction (FGR).
Materials and Methods: 41 pregnant women with FGR and 40 controls were recruited in this case-control study between July and November 2015. At the diagnosis of FGR, venous blood samples (10 cc) were obtained for FA analysis.
Results: Maternal plasma FA levels were significantly higher in fetal growth-restricted pregnant women compared with controls (19.3 ± 3.0 ng/ml vs 25.9 ± 6.8 ng/ml, p = 0.001). Area under receiver operating characteristic curve analysis of FA in FGR was 0.815 (95% confidence interval (CI): 0.718-0.912, p < 0.001). The maternal FA levels with values more than 22.5 ng/ml had a sensitivity of about 73.17% (95% CI: 56.79- 85.25) and a specificity of about 82.5% (95% CI: 66.64-92.11) with positive and negative predictive values of about 81.08% (95% CI: 64.29-91.45) and 75% (95% CI: 59.35-86.30), respectively. Therefore, the diagnostic accuracy was obtained about 77.78%.
Conclusion: The results of this study show higher maternal plasma levels of FA in FGR. Further studies are needed in order to demonstrate the long-term effects of FA in pregnancies complicated with FGR and early prediction of FFGR.
Type of Study: Original Article |
References
1. Organization WH. The world health report: 2002: Reducing risks, promoting healthy life. Geneva: World Health Organization; 2002.
2. American College of Obstetricians and Gynecologists. ACOG Practice bulletin no. 134: fetal growth restriction. Obstet Gynecol 2013; 121: 1122-1133. [DOI:10.1097/01.AOG.0000429658.85846.f9] [PMID]
3. Gordijn SJ, Beune IM, Thilaganathan B, Papageorghiou A, Baschat AA, Baker PN, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol 2016; 48: 333-339. [DOI:10.1002/uog.15884] [PMID]
4. Pallotto EK, Kilbride HW. Perinatal outcome and later implications of intrauterine growth restriction. Clin Obstet Gynecol 2006; 49: 257-269. [DOI:10.1097/00003081-200606000-00008] [PMID]
5. Doğan NÖ, Yalvaç S, Çalışkan E, Erten A, Dölen İ, Haberal A. Predictors of cord blood leptin level in pregnancies complicated with preeclampsia, fetal growth restriction and in normal pregnancies. Gynecol Obstet Reprod Med 2007; 13: 14-20.
6. Gaudineau A. [Prevalence, risk factors, maternal and fetal morbidity and mortality of intrauterine growth restriction and small-for-gestational age]. J Gynecol Obstet Biol Reprod 2013; 42: 895-910. (in Persian)
7. De Frene V, Vansteelandt S, T'Sjoen G, Gerris J, Somers S, Vercruysse L, et al. A retrospective study of the pregnancy, delivery and neonatal outcome in overweight versus normal weight women with polycystic ovary syndrome. Hum Reprod 2014; 29: 2333-2338. [DOI:10.1093/humrep/deu154] [PMID]
8. Ix JH, Shlipak MG, Brandenburg VM, Ali S, Ketteler M, Whooley MA. Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 2006; 113: 1760-1767. [DOI:10.1161/CIRCULATIONAHA.105.588723] [PMID] [PMCID]
9. Srinivas PR, Wagner AS, Reddy LV, Deutsch DD, Leon MA, Goustin AS, et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993; 7: 1445-1455. [DOI:10.1210/mend.7.11.7906861] [PMID]
10. Koos R, Brandenburg V, Mahnken AH, Muhlenbruch G, Stanzel S, Gunther RW, et al. Association of fetuin-A levels with the progression of aortic valve calcification in non-dialyzed patients. Eur Heart J 2009; 30: 2054-2061. [DOI:10.1093/eurheartj/ehp158] [PMID]
11. Dervisoglu E, Kir HM, Kalender B, Caglayan C, Eraldemir C. Serum fetuin--a concentrations are inversely related to cytokine concentrations in patients with chronic renal failure. Cytokine 2008; 44: 323-327. [DOI:10.1016/j.cyto.2008.08.014] [PMID]
12. Srinivas SK, Sammel MD, Bastek J, Ofori E, Andrela CM, Wolfe ML, et al. Evaluating the association between all components of the metabolic syndrome and pre-eclampsia. J Matern Fetal Neonatal Med 2009; 22: 501-509. [DOI:10.1080/14767050902794642] [PMID]
13. Iyidir OT, Degertekin CK, Yilmaz BA, Altinova AE, Toruner FB, Bozkurt N, et al. Serum levels of fetuin A are increased in women with gestational diabetes mellitus. Arch Gynecol Obstet 2015; 291: 933-937. [DOI:10.1007/s00404-014-3490-3] [PMID]
14. Tannetta D, Mackeen M, Kessler B, Sargent I, Redman C. OS045. Multi-dimensional protein identification technology analysis of syncytiotrophoblast vesicles released from perfused preeclampsia placentas. Pregnancy Hypertens 2012; 2: 201-202. [DOI:10.1016/j.preghy.2012.04.046] [PMID]
15. Zareaan E, Heidarpour M, Kargarzadeh E, Moshfeghi M. Association of maternal and umbilical cord blood leptin concentrations and abnormal color Doppler indices of umbilical artery with fetal growth restriction. Int J Reprod Biomed 2017; 15: 135-140. [DOI:10.29252/ijrm.15.3.135]
16. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-2194. [DOI:10.1001/jama.2013.281053] [PMID]
17. Karadeniz O, Mendilcioglu I, Ozdem S, Ozekinci M, Sanhal CY, Uzun G, et al. The association between ischaemia-modified albumin levels in umbilical vein and intrauterine growth restriction. J Obstet Gynaecol 2015; 35: 9-12. [DOI:10.3109/01443615.2014.930101] [PMID]
18. Sanhal CY, Can Kavcar M, Yucel A, Erkenekli K, Erkaya S, Uygur D. Comparison of plasma fetuin A levels in patients with early-onset pre-eclampsia vs late-onset pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 2016; 200: 108-112. [DOI:10.1016/j.ejogrb.2016.03.011] [PMID]
19. Creasy RK, Resnik R, Iams JD, Lockwood CJ, Moore TR. Creasy and resnik's maternal-fetal medicine: Principles and practice. 6th Ed. Philadelphia: Elsevier Saunders; 2014: 743-755.
20. Weichert A, Hagen A, Tchirikov M, Fuchs IB, Henrich W, Entezami M. Reference curve for the mean uterine artery pulsatility index in singleton pregnancies. Geburtshilfe Frauenheilkd 2017; 77: 516-523. [DOI:10.1055/s-0043-108764] [PMID] [PMCID]
21. Esercan A, Karakuş R, Özgü Erdinç AS. Aortic isthmus doppler for fetal assessment. Gynecol Obstet Reprod Med 2013; 19: 197-202.
22. Savchev S, Sanz-Cortes M, Cruz-Martinez R, Arranz A, Botet F, Gratacos E, et al. Neurodevelopmental outcome of full-term small-for-gestational-age infants with normal placental function. Ultrasound Obstet Gynecol 2013; 42: 201-206. [DOI:10.1002/uog.12391] [PMID]
23. Briana DD, Boutsikou M, Gourgiotis D, Boutsikou T, Baka S, Marmarinos A, et al. Serum fetuin-A/alpha2-HS-glycoprotein in human pregnancies with normal and restricted fetal growth. J Matern Fetal Neonatal Med 2008; 21: 826-830. [DOI:10.1080/14767050802326255] [PMID]
24. Karamessinis PM, Malamitsi-Puchner A, Boutsikou T, Makridakis M, Vougas K, Fountoulakis M, et al. Marked defects in the expression and glycosylation of alpha2-HS glycoprotein/fetuin-A in plasma from neonates with intrauterine growth restriction: proteomics screening and potential clinical implications. Mol Cell Proteomics 2008; 7: 591-599. [DOI:10.1074/mcp.M700422-MCP200] [PMID]
25. Gomez LM, Anton L, Srinivas SK, Elovitz MA, Parry S. Effects of increased fetuin-A in human trophoblast cells and associated pregnancy outcomes. Am J Obstet Gynecol 2012; 207: 484. e1-8. [DOI:10.1016/j.ajog.2012.10.872] [PMID]
26. Dabrowska AM, Tarach JS, Wojtysiak-Duma B, Duma D. Fetuin-A (AHSG) and its usefulness in clinical practice. Review of the literature. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159: 352-359. [DOI:10.5507/bp.2015.018] [PMID]
27. Dziegielewska KM, Brown WM, Gould CC, Matthews N, Sedgwick JE, Saunders NR. Fetuin: an acute phase protein in cattle. J Comp Physiol B 1992; 162: 168-171. [DOI:10.1007/BF00398343] [PMID]
28. Peltz ED, Moore EE, Eckels PC, Damle SS, Tsuruta Y, Johnson JL, et al. HMGB1 is markedly elevated within 6 hours of mechanical trauma in humans. Shock 2009; 32: 17-22. [DOI:10.1097/SHK.0b013e3181997173] [PMID] [PMCID]
29. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008; 118: 2555-2562. [DOI:10.1161/CIRCULATIONAHA.108.814418] [PMID]
30. Tuttolomondo A, Di Raimondo D, Di Sciacca R, Casuccio A, Bivona G, Bellia C, et al. Fetuin-A and CD40 L plasma levels in acute ischemic stroke: differences in relation to TOAST subtype and correlation with clinical and laboratory variables. Atherosclerosis 2010; 208: 290-296. [DOI:10.1016/j.atherosclerosis.2009.07.032] [PMID]
31. Kalagiri RR, Carder T, Choudhury S, Vora N, Ballard AR, Govande V, et al. Inflammation in complicated pregnancy and its outcome. Am J Perinatol 2016; 33: 1337-1356. [DOI:10.1055/s-0036-1582397] [PMID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
